Paromomycin
Based on 1 Customer Validation
Paromomycin (Aminosidine) is an orally active broad-spectrum aminoglycoside aminocyclitol. Paromomycin is produced by Streptomyces riomosus var. Paromomycinus. Paromomycin binding induces local conformational changes in the 16S rRNA A-site. Paromomycin exhibits inhibitory activity against C. parvum. Paromomycin can be used in research related to leishmaniasis, amoebiasis and cryptosporidiosis.
For research use only. We do not sell to patients.
- CAS No.: 7542-37-2
- Formula: C23H45N5O14
- Molecular Weight:615.63
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Paromomycin
MoreAll Parasite Isoforms
MoreAll Endogenous Metabolite Isoforms
More
Biological Activity
|
Microbial Metabolite |
Leishmania |
Amebae |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HCT-8 | IC50 |
711 nM
Compound: Paromomycin
|
Antimicrobial activity against Cryptosporidium parvum infected in human HCT-8 cells after 48 hrs by ELISA
Antimicrobial activity against Cryptosporidium parvum infected in human HCT-8 cells after 48 hrs by ELISA
|
[PMID: 18591280] |
| J774.A1 | CC50 |
53.33 μg/mL
Compound: Paromomycin
|
Cytotoxicity against mouse J774A1 cells by MTT assay
Cytotoxicity against mouse J774A1 cells by MTT assay
|
[PMID: 21295472] |
| Peritoneal macrophage cell | IC50 |
>100 μM
Compound: paromomycin
|
Cytotoxicity against mouse Peritoneal macrophages cells after 72 hrs by MTS assay
Cytotoxicity against mouse Peritoneal macrophages cells after 72 hrs by MTS assay
|
[PMID: 22989363] |
| RAW264.7 | IC50 |
>100 μM
Compound: paromomycin
|
Cytotoxicity against mouse RAW264.7 cells after 72 hrs by MTS assay
Cytotoxicity against mouse RAW264.7 cells after 72 hrs by MTS assay
|
[PMID: 22989363] |
| Vero | CC50 |
53.3 μM
Compound: Paromomycin
|
Cytotoxicity against african green monkey vero cells assessed as cell viability after 72 hrs by MTT assay
Cytotoxicity against african green monkey vero cells assessed as cell viability after 72 hrs by MTT assay
|
[PMID: 23673014] |
| Vero C1008 | IC50 |
>2.0 × 105M
Compound: COVC-0676336451
|
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging
|
10.6019/CHEMBL4651402 |
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6N (female, 6 weeks old, 14-16 g, immunosuppressed with dexamethasone phosphate, infected with Cryptosporidium parvum)[3]
-
Dosage:0.25 g/kg/day; 0.5 g/kg/day; 1 g/kg/day; 2 g/kg/day
-
Administration:p.o.; once daily; 10 consecutive days
-
Result:Significantly reduced fecal oocyst shedding (P < 0.01) at 1 g/kg/day and 2 g/kg/day, with no rebound after initial reduction.
Significantly lowered parasite colonization in ilea (0.02 ± 0.02 C.
parvum/epithelial cell at 1 g/kg/day; 0 C.
parvum/epithelial cell at 2 g/kg/day) and terminal ilea (0.15 ± 0.08 C.
parvum/epithelial cell at 1 g/kg/day; 0.03 ± 0.03 C.
parvum/epithelial cell at 2 g/kg/day) compared to placebo controls (P < 0.05).
Increased villus-to-crypt (V/C) ratios in ilea (1.99 ± 0.08 at 1 g/kg/day; 1.98 ± 0.02 at 2 g/kg/day) and terminal ilea (1.81 ± 0.11 at 1 g/kg/day; 1.91 ± 0.07 at 2 g/kg/day) compared to placebo controls (P < 0.05), indicating reduced villus atrophy.
Reduced oocyst shedding within 24 hours at 0.25 g/kg/day and 0.5 g/kg/day, but rebound occurred starting on day 14 post-infection with shedding exceeding pretreatment levels.
Showed no significant therapeutic benefit for parasite colonization or villus atrophy relative to placebo controls at 0.25 g/kg/day and 0.5 g/kg/day.
Chemical Information
-
CAS No. 7542-37-2
-
Molecular Weight 615.63
-
Formula C23H45N5O14
-
SMILES
O[C@H]([C@@H]([C@H](O1)CO)O[C@H]2O[C@H]([C@H]([C@@H]([C@H]2N)O)O)CN)[C@@H]1O[C@H]([C@H]([C@@H](C[C@@H]3N)N)O)[C@@H]3O[C@H]4O[C@@H]([C@H]([C@@H]([C@H]4N)O)O)CO
-
Synonyms
Aminosidine
-
Structure Classification
-
Initial Source
Streptomyces sp
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (4)
-
Journal Impact Factor
-
Most Recent
-
Int J Mol Sci
Discovery of TRPV4-Targeting Small Molecules with Anti-Influenza Effects Through Machine Learning and Experimental Validation. [Abstract]2025 Feb 6;26(3):1381. PMID: 39941149 -
Comput Biol Chem
Targeting quorum sensing in Pseudomonas aeruginosa with high-affinity inhibitors: A high-throughput screening and in-silico analysis. [Abstract]2025 Aug:117:108419. PMID: 40088808 -
Acta Trop
Paromomycin-loaded mannosylated chitosan nanoparticles: Synthesis, characterization and targeted drug delivery against leishmaniasis. [Abstract]2019 Sep:197:105045. PMID: 31158341 -
Vet Res Commun
Biological characterization of lipoic acid- and heme-dependent Escherichia coli small colony variants isolated from sheep in Xinjiang, China. [Abstract]2024 Dec;48(6):3859-3872. PMID: 39325108
Purity & Documentation
References
[1]. Sundar S, et al. Paromomycin in the treatment of leishmaniasis. Expert Opin Investig Drugs. 2008;17(5):787-794. [Content Brief]
[2]. Fourmy D, et al. Paromomycin binding induces a local conformational change in the A-site of 16 S rRNA. J Mol Biol. 1998;277(2):333-345. [Content Brief]
[3]. Healey MC, et al. Therapeutic efficacy of paromomycin in immunosuppressed adult mice infected with Cryptosporidium parvum. J Parasitol. 1995;81(1):114-116. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Powered by Bioz